LiDCO Group plc announced that it has had further success in the USA contracting a large public university medical centre in Southern California to its differentiated High Usage Programme (HUP) business model. The customer has signed a five-year agreement for 15 monitors, fully converting from their current hemodynamic monitoring provider. The centre is a recognised thought leader in the US in the treatment of Sepsis, the leading cause of death in hospitals and re-admissions. LiDCO's technology has been strongly associated with successful treatment protocols for this patient population and there are a number of clinical papers demonstrating the benefits of using LiDCO technology within this patient group. In one such study, Hata et al investigated the mortality of 237 patients who developed Sepsis, the research group concluded using the LiDCO technology in this high-risk patient group reduced mortality by 24% through better management and early detection. HUP continues to build momentum in the US. Since the start of the calendar year the Company has now won three new HUP customers, signing contracts for 38 monitors with an annualised revenue of $0.5 million. Since launching the HUP programme in July 2017, the Company now has 129 HUP monitors in the US generating contracted annualised recurring revenues in excess of $1.5m. This greatly enhances revenue visibility and reduces the challenges of closing orders around the year-end.